← back to search

Fugen Li

Massachusetts Institute of Technology · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Biology, Medicine, Cancer research, Breast cancer, Internal medicine, and Chromatin.
h-index
citations
2,605
works
17
NIH funding
primary concept
email

Recent publications

A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
Journal of Hematology & Oncology 2025cited by 1position: middledoi
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer
Translational Lung Cancer Research 2025cited by 1position: middledoi
A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
Blood 2023cited by 3position: middledoi
Development and Validation of an RNA Sequencing Assay for Gene Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tumors
Journal of Molecular Diagnostics 2020cited by 18position: middledoi
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
JAMA Oncology 2019cited by 495position: middledoi
Prognostic implications of a molecular classifier derived from whole‐exome sequencing in nasopharyngeal carcinoma
Cancer Medicine 2019cited by 29position: middledoi
The characteristics of ctDNA reveal the high complexity in matching the corresponding tumor tissues
BMC Cancer 2018cited by 75position: lastdoi
Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients.
PubMed 2018cited by 1position: middle
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance
Proceedings of the National Academy of Sciences 2017cited by 113position: middledoi
Differential impact of RB status on E2F1 reprogramming in human cancer
Journal of Clinical Investigation 2017cited by 103position: middledoi
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
Proceedings of the National Academy of Sciences 2016cited by 184position: middledoi
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation
Nature Communications 2016cited by 58position: middledoi
The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Nature Genetics 2015cited by 486position: middledoi
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions
Human Molecular Genetics 2015cited by 41position: middledoi
Broadly permissive intestinal chromatin underlies lateral inhibition and cell plasticity
Nature 2014cited by 263position: middledoi
Dynamic and Coordinated Epigenetic Regulation of Developmental Transitions in the Cardiac Lineage
Cell 2012cited by 632position: middledoi
Admixture and recombination among <i>Toxoplasma gondii</i> lineages explain global genome diversity
Proceedings of the National Academy of Sciences 2012cited by 102position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Myles Brown · Harvard University3 papers (2015–2017)Henry W. Long · Harvard University3 papers (2014–2017)Yue-Rong Shuang · Nanchang University2 papers (2023–2025)Zhigang Peng · Central South University2 papers (2023–2025)Stuart S. Levine · Massachusetts Institute of Technology2 papers (2012–2012)He Huang · Zhejiang Chinese Medical University2 papers (2023–2025)Ramesh A. Shivdasani · Boston Medical Center2 papers (2014–2015)Hui Zhou · Sun Yat-sen University Cancer Center2 papers (2023–2025)Huangming Hong · University of Electronic Science and Technology of China2 papers (2023–2025)Michaela Bowden · Moderna Therapeutics (United States)2 papers (2015–2017) · 2 papers (2023–2025)Fei Li · New York University2 papers (2023–2025)Mingzhi Zhang · Shanghai University2 papers (2023–2025)Lihong Liu · Hebei Medical University2 papers (2023–2025)Liang Wang · Beijing Tongren Hospital2 papers (2023–2025)Liling Zhang · Sun Yat-sen University Cancer Center2 papers (2023–2025) · 2 papers (2023–2025)Meng Li · Gansu Provincial Hospital2 papers (2023–2025)Qian Shen · Wuhan Polytechnic University2 papers (2023–2025)Pengcheng He · Guangzhou University of Chinese Medicine2 papers (2023–2025)